Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eupraxia Pharmaceuticals Inc (EPRX.TO)

Eupraxia Pharmaceuticals Inc (EPRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 151,396
  • Shares Outstanding, K 35,623
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,221 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.36
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.93
  • Most Recent Earnings $-0.17 on 11/07/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +37.46%
on 10/22/24
5.10 -17.25%
on 11/01/24
+0.90 (+27.11%)
since 10/15/24
3-Month
3.07 +37.46%
on 10/22/24
5.10 -17.25%
on 11/01/24
+0.62 (+17.22%)
since 08/15/24
52-Week
3.07 +37.46%
on 10/22/24
7.64 -44.76%
on 02/13/24
-2.32 (-35.47%)
since 11/15/23

Most Recent Stories

More News
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
BRE.TO : 14.75 (-3.59%)
Stocks in play: Eupraxia Pharmaceuticals Inc.

Will be presenting two posters at the American College of Gastroenterology Annual Scientific Meeting ...

EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)
Eupraxia Pharmaceuticals Strengthens Senior Management Team

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 3.14 (+8.28%)
EPRX.TO : 4.39 (+3.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages...

See More

Key Turning Points

3rd Resistance Point 4.57
2nd Resistance Point 4.41
1st Resistance Point 4.33
Last Price 4.39
1st Support Level 4.09
2nd Support Level 3.93
3rd Support Level 3.85

See More

52-Week High 7.64
Fibonacci 61.8% 5.89
Fibonacci 50% 5.36
Fibonacci 38.2% 4.82
Last Price 4.39
52-Week Low 3.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar